FDA approves RVMD’s RASONQUE for metastatic pancreatic cancer
The U.S. FDA has approved Revolution Medicines’ RASONQUE™ (daraxonrasib) for metastatic pancreatic cancer,
Story updates
05:07:46 PM UTC
SquawkNews
U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.